MannKind (MNKD) is back in focus after securing a Breakthrough T1D grant to support its INHALE-1 pediatric trial of Afrezza inhaled insulin in newly diagnosed type 1 diabetes patients.

Against this grant backdrop, MannKind’s share price has shown strong recent momentum, with a 30 day share price return of 11.33% and a 90 day share price return of 72.37%, even though the year to date share price return is down 29.82% and the 1 year total shareholder return is 4.24%.

If Afrezza’s pediatric progress has your attention, it could be a good time to broaden your watchlist and check out 39 healthcare AI stocks

With MannKind now trading at $3.93 and sitting at a large discount to the average analyst price target, the key question is whether current levels still underappreciate Afrezza’s pediatric potential or whether the stock already reflects future growth.

Most Popular Narrative: 48.2% Undervalued

At a last close of $3.93 versus a narrative fair value of $7.59, MannKind is framed as heavily undervalued, with Afrezza and the inhaled pipeline doing most of the heavy lifting in that story.

Multiple late-stage pipeline programs (inhaled clofazimine for NTM and nintedanib DPI for IPF) are progressing toward key regulatory and clinical milestones, benefiting from expedited pathways and growing unmet need in chronic respiratory diseases, with the potential to significantly diversify and expand future revenues.

Want to see how this expands beyond Afrezza and pediatrics? The narrative leans on ambitious revenue growth, margin expansion and a rich future earnings multiple. The underlying assumptions might surprise you.

Result: Fair Value of $7.59 (UNDERVALUED)

However, this MannKind narrative can unravel quickly if Afrezza remains a niche product with limited adoption, or if core royalty streams face competitive or regulatory setbacks.

Next Steps

With investors split between Afrezza’s promise and the risks around adoption and royalties, it makes sense to move quickly and test the numbers for yourself, starting with the balance of 3 key rewards and 1 important warning sign

Looking for more MannKind sized opportunities?

If MannKind has reignited your interest in fresh ideas, do not stop here. Use the Simply Wall Street screener to hunt for the next stock that deserves your attention.

• Target higher quality potential by reviewing companies trading at appealing valuations through the 43 high quality undervalued stocks.
• Strengthen your portfolio’s foundation by focusing on resilient businesses highlighted in the 67 resilient stocks with low risk scores.
• Spot future contenders early by working through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.